Predictive biomarkers of prostate cancer patient sensitivity for radiation late effects

Ended Definitive Contract Awarded

Contract number
HHSN261201600027C
Awardee
Awarding agency
Obligated
$299,502

Award facts

Opportunity
  • PHS20161 Solicitation number
Contract value 100% obligated
$299,502.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541711 Research and Development in Biotechnology
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Rockville, MD 20850, USA
Research
SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

About this award

The U.S. National Cancer Institute awarded a $299,502 Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a small business located in Gaithersburg, Maryland. The contract is for the development of "Predictive Biomarkers of Prostate Cancer Patient Sensitivity for Radiation Late Effects." This is a Firm Fixed Price definitive contract with a period of performance through September 18, 2017.

Quick answers

Who was awarded contract HHSN261201600027C?

HHSN261201600027C was awarded to Shuttle Pharmaceuticals, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.

How much is contract HHSN261201600027C worth?

The government has obligated $299,502 on HHSN261201600027C.

Was contract HHSN261201600027C competed?

The extent of competition for HHSN261201600027C was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award